2022
DOI: 10.1111/ced.15044
|View full text |Cite
|
Sign up to set email alerts
|

Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia

Abstract: We read with great interest the recently published article by Joos et al. on the successful use of baricitinib for cutaneous lupus erythematosus. The authors presented a heavily pretreated case of subacute cutaneous lupus erythematosus (SCLE) with almost complete clearance following 6 months of baricitinib therapy. We would like to add our experiences of baricitinib for SCLE in a patient with concomitant frontal fibrosing alopecia.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 5 publications
0
8
0
Order By: Relevance
“… Resulted in complete remission of all lesions within 4 months. Kreuter (2021) 14 Case report Baricitinib 4mg daily for 2 months, then ongoing 2mg daily maintenance A 62-year-old woman with a 4-year history of FFA and SCLE resistant to several previous medications including chloroquine, hydroxychloroquine, methotrexate, azathioprine and rituximab. Resulted in complete clearance of SCLE and stopped further progression of FFA.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“… Resulted in complete remission of all lesions within 4 months. Kreuter (2021) 14 Case report Baricitinib 4mg daily for 2 months, then ongoing 2mg daily maintenance A 62-year-old woman with a 4-year history of FFA and SCLE resistant to several previous medications including chloroquine, hydroxychloroquine, methotrexate, azathioprine and rituximab. Resulted in complete clearance of SCLE and stopped further progression of FFA.…”
Section: Resultsmentioning
confidence: 99%
“…A 62-year-old woman showed complete clearance of SCLE after treatment with baricitinib 4 mg daily for 2 months followed by an ongoing daily maintenance dose of 2 mg. Interestingly, the treatment also halted the progression of this patient’s frontal fibrosing alopecia (FFA). 14 A case series of three patients with familial chilblain lupus (FCL) showed significant improvement of all cutaneous lesions after three months of baricitinib 4 mg daily. 15 Additional case reports displaying baricitinib’s efficacy are shown in Table 1 .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, a case report showed promising results with JAK1/2 inhibitor. Subacute cutaneous lupus erythematosus (SCLE) with frontal fibrosing alopecia (FFA) presented a complete remission after 2 months of barcitinib therapy [ 63 ].…”
Section: Jak–stat Pathwaymentioning
confidence: 99%
“…Two studies have described the use of JAK inhibitors in the treatment of CLE, using the SLE Disease Activity Index 2000 as the main end point which is not specific to skin disease (126,127). Baricitinib showed complete remission of a refractory papulosquamous rash in an SLE patient (128) and complete clearance of subacute CLE and no further progression of the FFA in a patient who was started on baricitinib 4 mg for 2 months, followed by ongoing maintenance therapy with baricitinib 2 mg (129).…”
Section: Janus Kinase Inhibitorsmentioning
confidence: 99%